Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:6000:d0:b0:439:fcfb:30e with SMTP id q16csp1875192wrx; Tue, 31 Mar 2026 08:14:10 -0700 (PDT) X-Received: by 2002:a05:6214:450a:b0:899:f24d:1245 with SMTP id 6a1803df08f44-89ce8ea085amr247991006d6.43.1774970050298; Tue, 31 Mar 2026 08:14:10 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774970050; cv=none; d=google.com; s=arc-20240605; b=ABHseI74lBz1KA+TsA8igbAOLX6btqYowtzofu4FKWtYOXdAI7UFLRkyQVFaFnw630 oA2UNhzKxDuGEEeqczcAEYtwzATsPzNywY+QqSf0KmqWWOrrxQyyG2cQchLDXxFaamIT Uq0tS0L5qElHS07KUUkmloQcyuEyRydi2mw7KNdmt6duyIQaje1d05q5S6H+00h/MAG9 rDB5glz9a05Fs420m5eKNViGeWkN4BfDWtHrvyiBUl7W52SHM8WP3trtGJiwlNsYEAuv TlFufCqJjrkvyY9T6PsHxlXYJ9hdYkEvN/z337QGMH76bR/1OLk3pS6UNEmbg93RDmUK nrMg== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:list-unsubscribe-post:feedback-id:list-unsubscribe:to :from:subject:mime-version:date:sender:dkim-signature:dkim-signature :dkim-signature; bh=xJid+g+PF5E3aV9Kn17QYzheo7fTqJm1/6AY3+yNeRU=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=kOrb9gU6tW7NIk/vGKcKDemu5NoLxD7X6cgKKEOsxDGYyEtcZE+zvXyVZ/P+IW/ebo jBJME3EopLgwjbm75/PcNVlnFh2RtAGXTdAVaOPfY/zLB62qFg+3dsSCA4XIVtJui0c6 X/H5R29/Q0A3+PWCydTjj/SPgxB8SnaejxG1t84dmyy3k+x4VmeSnZlplwL0nM2yQnX/ LNk6PuW9LoTykAhE4ntEXw9Pow7YgXVWnHikgVk1TkikFXsPxiSNaQL4P7C52uMkNXgn 2vWGkoA+c68kaRC8GiLneoXF6+l/o7ZMHU7JjTvxnuNWf4WUTkDrT8YO+C5yHyUnN8lD c31g==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@dkim1.omnisend.email header.s=omni2 header.b=q9hwOzWv; dkim=pass header.i=@simplepeptide.com header.s=mx header.b=JHAVKCNo; dkim=pass header.i=@mailgun.org header.s=mg header.b=hI70CBIU; spf=pass (google.com: domain of bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com designates 204.220.169.118 as permitted sender) smtp.mailfrom="bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com"; dmarc=pass (p=QUARANTINE sp=QUARANTINE dis=NONE) header.from=simplepeptide.com Return-Path: Received: from g118.gb126d70.use4.send.mailgun.net (g118.gb126d70.use4.send.mailgun.net. [204.220.169.118]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-89ed15bec01si129239386d6.567.2026.03.31.08.14.09 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Tue, 31 Mar 2026 08:14:10 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com designates 204.220.169.118 as permitted sender) client-ip=204.220.169.118; Authentication-Results: mx.google.com; dkim=pass header.i=@dkim1.omnisend.email header.s=omni2 header.b=q9hwOzWv; dkim=pass header.i=@simplepeptide.com header.s=mx header.b=JHAVKCNo; dkim=pass header.i=@mailgun.org header.s=mg header.b=hI70CBIU; spf=pass (google.com: domain of bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com designates 204.220.169.118 as permitted sender) smtp.mailfrom="bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com"; dmarc=pass (p=QUARANTINE sp=QUARANTINE dis=NONE) header.from=simplepeptide.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=dkim1.omnisend.email; q=dns/txt; s=omni2; t=1774970049; x=1774977249; h=Message-Id: List-Unsubscribe-Post: List-Unsubscribe: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: Sender: Sender: X-Feedback-Id; bh=xJid+g+PF5E3aV9Kn17QYzheo7fTqJm1/6AY3+yNeRU=; b=q9hwOzWvRJLQk+AyrXacO/misR48qeSzI3AhOQaiC5fufAZTHY/3DG6J926MFIZozWkw30w2DActgLO/ggIp+J+w78RvKv4eMzsfc5SaXgI4qgbFUk5fziXxVdAaNHjs9AKpYXvRViyTDH4pBfKQYTtuNvAk8PeBPLyfxkhO09aKay9al7VgO22ffaQVQw4HIHArQpABfsNZnyhI1izQRxL8Dp+WQlKGR7Ygf8QKWUIyvVV11jeE4M2Xf5ebavvZZEO11xTJTcwix8zkCSVprq/clSnmmftAH+1KdvAJ36xONmp5VsbuBQnjzoWltRhJds6jk779AildB5ZEdgxA9w== DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=simplepeptide.com; q=dns/txt; s=mx; t=1774970049; x=1774977249; h=Message-Id: List-Unsubscribe-Post: List-Unsubscribe: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: Sender: Sender: X-Feedback-Id; bh=xJid+g+PF5E3aV9Kn17QYzheo7fTqJm1/6AY3+yNeRU=; b=JHAVKCNoSdwwSAtjOYtYPMSmtudymMJwdAIL+2/SlZc9FgpYYnKNmpk+3RjtBWTbvMYbU2tC+Q6mHM0NZwVy0asC0Y4M0af8xh+1NEvD2Ob5IVzf5GO4psiADOBX9hVIvWEtfsjzbFM+HnMFKOEu9ZnSUTuZvaIykwljdzfwyrQ= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1774970049; x=1774977249; h=Message-Id: List-Unsubscribe-Post: List-Unsubscribe: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: Sender: Sender: X-Feedback-Id; bh=xJid+g+PF5E3aV9Kn17QYzheo7fTqJm1/6AY3+yNeRU=; b=hI70CBIU7OVqIt819OtzPnSu4fwpPR6Fw50eplwtwN9HGBX15oiNtGNOchCp8pX/ev/Cqh+DlUSqVX6zMEiSyQi79ZGyRh9NDxy8hIj8u4hM6ywn6tpP5x+IHvOWWeHxHW/EBhiJYF0B2zBYEIARV9AdAFHeagvgHbxoJaB3In4= X-Mailgun-Sid: WyJiMTY3ZiIsInRqcGh1aHNAZ21haWwuY29tIiwiMWUzMjBmOSJd X-Feedback-Id: support@simplepeptide.com:secondary-dkim-signed:6842137ba5beeb5ef138be2e:mailgun Received: by 3f0a0e7bf52d7829fe5605524817500f0ce907ae752eb230fb63557a60e4de1a with HTTP id 69cbe4c1a94d5b8809f8d32c; Tue, 31 Mar 2026 15:14:03 GMT X-Mailgun-Sending-Ip-Pool-Name: BstS X-Mailgun-Sending-Ip-Pool: 665596289f43bfa346f3584f X-Mailgun-Sending-Ip: 204.220.169.118 X-Mailgun-Batch-Id: 69cbe4bb29f95355fc10d795 Sender: support@simplepeptide.com Date: Tue, 31 Mar 2026 15:14:03 +0000 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="45e69781ca7942a1f3ca7dc9ac041738a2c2beaa4d14889639254a819910" Subject: Introducing the Next Generation of Natural Rejuvenation From: Simple Peptide To: tjphuhs@gmail.com X-Mailgun-Tag: secondary-dkim-signed X-Mailgun-Track: false X-Mailgun-Secondary-Dkim: dkim1.omnisend.email,omni2 List-Unsubscribe: Feedback-Id: 69ca671d4cee8e5fcc2a06e6:68405b213a5771675694ea59:campaign:omnisend List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"brandID": "68405b213a5771675694ea59", "contactID": "6864b11c9f318c74accf8c6b", "progressID": "69ca9299d363e911a8b386ed"} Message-Id: <20260331151403.9e6fd662b8a72d3f@simplepeptide.com> --45e69781ca7942a1f3ca7dc9ac041738a2c2beaa4d14889639254a819910 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable A closer look at exosome-based formulations and a small naming update This email was sent to you as HTML-only. To view it, please visit:=20 https://ptv.soundestlink.com/ce/v/6864b11c9f318c74accf8c6b/69ca9299d363e911= a8b386ed ************************** Make sure you keep getting our latest offers and add support@simplepeptide.= com to your address book. Unsubscribe=20 https://ptv.soundestlink.com/contactsPreferences/v2/unsubscribe/?b=3D68405b= 213a5771675694ea59&c=3D6864b11c9f318c74accf8c6b&payload=3DdM17IfFW-ZLRfEW8y= ytMQJYfSQ7bA_xaQmjvhi8vreJRXFRT-aW7mJBcoY1Ee4hYVE9aGR2_7xoFeqwN6TFHjuMXf28M= vH1JMQ48Gg2dW1TjKq9pf20McRAOJvjTLNSu7yNq Visit site https://simplepeptide.com =C2=96 --45e69781ca7942a1f3ca7dc9ac041738a2c2beaa4d14889639254a819910 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Introducing the Next Generation of Natural Rejuvenation

= A closer look at exosome-based formulations and a small naming update

=
͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­

= 3D""
=
3D""
3D"c=

Dear Simple Pep= tide Community,


As research= and formulation science continue to evolve, exosome-based systems have bec= ome an increasing area of interest within cosmetic and laboratory-focused e= nvironments.


Exo= somes are often explored in structured settings for their role in = supporting skin-focused formulation models, particularly in areas related t= o renewal processes, absorption dynamics, and multi-component delivery syst= ems.


Within topi= cal and external-use formulations, researchers frequently examine how these= systems interact with surrounding compounds, helping to better understand = stability, consistency, and performance across controlled conditions.

=
 

Today, we=E2=80=99= re highlighting two formulations currently available within our catalog:

3D""

Ascellos=E2=84=A2 Exosomes

= An external-use formulation utilized in studies ex= ploring advanced cosmetic systems and next-generation rejuvenation-focused = models.


These types of formulations continue to suppor= t ongoing exploration into how structured delivery systems behave within co= ntrolled research settings.

Ascellos=E2=84=A2 Delivery System Considerations

3D""

= In addition to formulation composition, delivery m= ethods are also a key area of interest in cosmetic and laboratory-focused r= esearch.


The NanoPen Pro is commonly utilized in contro= lled environments exploring topical application techniques and surface-leve= l delivery systems. Researchers may incorporate this type of device when ev= aluating how formulations are distributed across the skin surface and how a= pplication methods influence consistency and absorption behavior within str= uctured testing conditions.


When paired with topical systems, delivery too= ls such as this can support more standardized application protocols during = experimental observation.

3D""

HyperGlow TXA-5=E2=84=A2 Brightening Serum=

A = serum-based formulation designed for research environments evaluating skin = appearance systems, tone consistency, and multi-ingredient interaction with= in a topical base.

=
 

Update: Adjustment= to GLP Naming Convention

As part of our = continued effort to align with evolving platform and compliance standards, = we have updated select product naming conventions:


GLP= -1SG is now SP-1SG

GLP-2TZ= is now SP-2TZ

GLP-3RT= is now SP-3RT


These updat= es apply to naming only. All underlying formulations and specifications rem= ain the same.


Select GLP = formulations currently remain available at 20% off, where applicable.


We appreciate your continued tr= ust as we provide structured, research-focused formulations designed for ev= olving areas of study.


Sincerely,The Simple Peptid= e Team

3D"3=
=
 

Follow us for= news, updates and special upcoming promotions!

3D"facebook" 3D"instagram"

Edit preferences or Unsubscribe

--45e69781ca7942a1f3ca7dc9ac041738a2c2beaa4d14889639254a819910--